Harnessing immune responses in the tumor microenvironment: All signals needed

Dung T. Le; Elizabeth M. Jaffee

doi:10.1158/1078-0432.CCR-13-2424

Harnessing immune responses in the tumor microenvironment: All signals needed

School of Medicine

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.

Original language	English (US)
Pages (from-to)	6061-6063
Number of pages	3
Journal	Clinical Cancer Research
Volume	19
Issue number	22
DOIs	https://doi.org/10.1158/1078-0432.CCR-13-2424
State	Published - Nov 15 2013

ASJC Scopus subject areas

General Medicine

Access to Document

10.1158/1078-0432.CCR-13-2424

Cite this

@article{7ea20aa281254b64b3dbb048346ff93a,

title = "Harnessing immune responses in the tumor microenvironment: All signals needed",

abstract = "An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.",

author = "Le, \{Dung T.\} and Jaffee, \{Elizabeth M.\}",

year = "2013",

month = nov,

day = "15",

doi = "10.1158/1078-0432.CCR-13-2424",

language = "English (US)",

volume = "19",

pages = "6061--6063",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "22",

}

TY - JOUR

T1 - Harnessing immune responses in the tumor microenvironment

T2 - All signals needed

AU - Le, Dung T.

AU - Jaffee, Elizabeth M.

PY - 2013/11/15

Y1 - 2013/11/15

N2 - An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.

AB - An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.

UR - https://www.scopus.com/pages/publications/84888112421

UR - https://www.scopus.com/pages/publications/84888112421#tab=citedBy

U2 - 10.1158/1078-0432.CCR-13-2424

DO - 10.1158/1078-0432.CCR-13-2424

M3 - Article

C2 - 24097857

AN - SCOPUS:84888112421

SN - 1078-0432

VL - 19

SP - 6061

EP - 6063

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 22

ER -

Harnessing immune responses in the tumor microenvironment: All signals needed

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this